IgA Nephropathy Takes Center Stage with Various Patient and Payer Events in July
Calliditas Therapeutics US is actively raising awareness for IgA nephropathy (IgAN), a rare kidney disease, through various events in July 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Calliditas Therapeutics US is actively raising awareness for IgA nephropathy (IgAN), a rare kidney disease, through various events in July 2022. The company, which has the first FDA-approved treatment for IgAN, emphasizes the importance of patient advocacy in supporting affected individuals and their caregivers. Initiatives include the Rare Kidney Disease Week from July 18-22, a webinar on July 21, and the SPARK 2022 symposium on July 24-25. Additionally, Calliditas launched the IgAN Connect educational campaign to provide resources and support for those living with the disease.
Positive
- First FDA-approved treatment for IgA nephropathy launched in December 2021.
- Initiatives aim to boost awareness and support for IgAN patients and caregivers.
Negative
- None.
Details
News Market Reaction – CALT
The recorded move for CALT in the trading session of this news was +0.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- As part of its ongoing commitment to raise awareness of both the unique challenges faced by people living with IgA nephropathy and of the resources and support required to help them navigate their journey, Calliditas Therapeutics US, a wholly owned affiliate of Sweden-based Calliditas Therapeutics AB focused on advancing care and treatment for rare kidney disease, recognizes and is supporting various events this month.
IgA nephropathy, or IgAN, is a progressive chronic disease that over time results in deterioration of kidney function in patients, many of whom end up at risk of developing end-stage renal disease, or ESRD, with the need for dialysis or kidney transplant. The first and only FDA-approved treatment specifically designed for the disease was approved in December 2021, and as a rare disease, advocacy remains an integral part of raising awareness for the disease and potential treatment options.
“Patient advocacy groups are instrumental in supporting a rare disease community, including patients and caregivers, through the difficult process of discovering and managing their disease,” says Andrew Udell, President of North America, Calliditas Therapeutics. “We’re happy to support these organizations as they continue to accelerate research, empower individuals and instill a strong network of support for the IgA nephropathy community.”
Calliditas acknowledges several patient and payer events focused on raising awareness for IgAN in the month of July.
- NephCure’s inaugural Rare Kidney Disease Week 2022 that will take place July 18-22, with a virtual "Rare Kidneys on the Hill Day" on July 19 to build further awareness of rare kidney diseases.
- For payers, in partnership with the Academy of Managed Care Pharmacy, Calliditas will also be hosting a live webinar entitled "A Novel Approach to the Treatment of IgA Nephropathy" on July 21, 2-3 pm ET. Click here to register.
- IGA Nephropathy Foundation’s SPARK 2022 symposium, July 24-25, for people with IgAN and their caregivers to learn about the disease, living with the disease and being a caregiver for those with the disease.
Calliditas recently launched IgAN Connect, an educational campaign where patients, caretakers and advocates can learn more about IgAN, discover ways to manage treatment and find resources for those living with the disease. The complementary IgAN Connect Facebook page offers additional educational and motivational resources for the IgAN community.
For a complete list of resources please click here.
This press release is for audiences in the United States.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
For further information, please contact:
Sky Striar, Calliditas Media Contact, LifeSci Communications
Tel: +1.617.797.6672; email: sstriar@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.